IAPN:一个简单的框架,用于评估基于人口的风险分层工具在实施之前是否具有成本效益
Steven Wyatt1, Mohammed A Mohammed2,3, Peter Spilsbury2
1The Strategy Unit - NHS Midlands and Lancashire Commissioning Support Unit, Birmingham, UK. swyatt@nhs.net.
Cost effectiveness and resource allocation : C/E
|December 5, 2024
概括
评估医疗风险预测工具需要评估成本效益以及统计绩效. 一个新的框架整合了积极的预测值 (PPV) 和干预效率 (NNT) 来确定实施前的经济可行性.
科学领域:
- 医疗保健分析 医疗保健分析
- 临床决策支持 临床决策支持
- 卫生经济学 卫生经济学
背景情况:
- 风险预测工具对于识别高风险患者至关重要,但往往缺乏成本效益评估.
- 传统的性能指标 (灵敏度,特异性) 不能保证实际的有效性或成本节省.
相关概念视频
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
120
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
120
Hazard Ratio
90
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
90
Comparing the Survival Analysis of Two or More Groups
150
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
150
Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328
Kaplan-Meier Approach
98
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
98
Actuarial Approach
63
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
63


